Search
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.
Categories: Serotonin Receptor Agonists, Serotonin-4 Receptor AgonistHexachlorophene
go.drugbank.com/drugs/DB00756ApprovedWithdrawnIt is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)
International brands: Pre-Op IIClobutinol
go.drugbank.com/drugs/DB09004ApprovedWithdrawnClobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.
Ornithine
go.drugbank.com/drugs/DB00129ApprovedInvestigationalNutraceuticalProduced during the urea cycle, ornithine is an amino acid produced from the splitting off of urea from arginine.
Mixtures: Primene 10%-liq IVClodronic acid
go.drugbank.com/drugs/DB00720ApprovedInvestigationalVet approved[A203111] Clodronic acid is not FDA approved, but is approved in Canada.[L13910] … Clodronic acid is a first generation bisphosphonate similar to [etidronic acid] and [tiludronic acid].
Fenoterol
go.drugbank.com/drugs/DB01288ApprovedWithdrawnFenoterol is an adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
Mixtures: Duovent Nebuliser solution in Unit Dose Vial 4mlCategories: Adrenergic beta-2 Receptor AgonistsCangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalAn advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset … Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.
Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor AntagonistsPlozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigationalPlozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference. … [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]
Atacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. … [L63797] Reducing BAFF- and APRIL-mediated signaling lowers production of galactose-deficient IgA1, an aberrant antibody whose deposition in the kidney drives IgA nephropathy.
Synonyms: TACI-IGZiconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be … [A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.
Categories: Compounds used in a research, industrial, or household setting, N-Calcium Channel Receptor Antagonists